^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
177Lu-LNC1004
i
Other names: 177Lu-LNC1004, 177Lu-EB-FAPI
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dongcheng Pharma
Drug class:
Beta radiation emitter, FAP inhibitor
Related drugs:
6d
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) (clinicaltrials.gov)
P2, N=35, Recruiting, Institut Curie | Not yet recruiting --> Recruiting
Enrollment open
|
177Lu-LNC1004
3ms
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection (clinicaltrials.gov)
P1, N=11, Completed, Yantai LNC Biotechnology Singapore PTE. LTD. | Recruiting --> Completed | N=24 --> 11 | Trial completion date: Mar 2025 --> Sep 2024 | Trial primary completion date: Mar 2025 --> Sep 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
177Lu-LNC1004
6ms
INDIGO-FAPI: Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (clinicaltrials.gov)
P2, N=35, Not yet recruiting, Institut Curie | Initiation date: Jan 2025 --> Sep 2025
Trial initiation date
|
177Lu-LNC1004
8ms
Evaluation of the efficacy and safety of 177Lu-LNC1004 injection in advanced gastrointestinal cancer patients with fibroblast activation protein (FAP) positivity (ChiCTR2500098383)
P1, N=6, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
New P1 trial
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
8ms
Study of 177Lu-LNC1004 injection for patients wiht radioactive iodine refractory differentiated thyroid cancer (ChiCTR2500096622)
P1, N=20, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
New P1 trial
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
9ms
177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study. (PubMed, Clin Cancer Res)
FAP-directed RLT using 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated with an acceptable toxicity profile. Nearly half of patients achieved disease control, which was associated with prolonged PFS and OS.
P2 data • Journal
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
1year
INDIGO-FAPI: Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (clinicaltrials.gov)
P2, N=35, Not yet recruiting, Institut Curie
New P2 trial
|
177Lu-LNC1004
over1year
Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. (PubMed, Signal Transduct Target Ther)
This was emphasized by the observed increase in antigen processing and presentation juxtaposed with T cell inactivation. In conclusion, our data supported the efficacy of immunotherapy combined with 177Lu-LNC1004 for cancer patients with FAP-positive tumors.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD8 (cluster of differentiation 8) • FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
2years
CISPD-5: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors (clinicaltrials.gov)
P1, N=29, Recruiting, Zhejiang University
New P1 trial • Metastases
|
177Lu-LNC1004
almost3years
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Yantai LNC Biotechnology Singapore PTE. LTD.
New P1 trial
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
Share via
